Kidney transplant recipients carrying the CYP3A4∗22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations

American Journal of Transplantation

Volumn 15, Issue 3, 2015, Pages 800-805

  Pallet, Nicolas ^a,b,c   Jannot, A S ^a,b,c   El Bahri, M ^a   Etienne, I ^d   Buchler, M ^e   De Ligny, B H ^f   Choukroun, G ^g   Colosio, C ^h   Thierry, A ⁱ   Vigneau, C ^j   Moulin, B ^k   Le Meur, Y ^l   Heng, A E ^m   Subra, J F ⁿ   Legendre, C ^o   Beaune, P ^a,b,c   Alberti, C ^p   Loriot, M A ^a,b,c   Thervet, E ^a,b,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

^f CAEN UNIVERSITY HOSPITAL   (France)

^g AMIENS UNIVERSITY HOSPITAL   (France)

^h REIMS UNIVERSITY HOSPITAL   (France)

ⁱ POITIERS UNIVERSITY HOSPITAL   (France)

^j RENNES UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^l BREST UNIVERSITY HOSPITAL   (France)

^m UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁿ ANGERS UNIVERSITY HOSPITAL   (France)

^o HÔPITAL NECKER ENFANTS MALADES   (France)

^p HÔPITAL ROBERT DEBRÉ   (France)

more..

Author keywords

Clinical research; immune modulation; immunosuppressant, calcineurin inhibitor: tacrolimus, pharmacokinetics; nephrology, immunosuppression; pharmacodynamics, genetics; pharmacology, kidney transplantation; practice

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; TACROLIMUS; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; GENETICS; MIDDLE AGED;

ADULT; ALLELES; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS;

EID: 84923309456     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13059     Document Type: Article

References (16)

1. Elens L, Hesselink DA, van Schaik RH, van Gelder T,. Pharmacogenetics in kidney transplantation: Recent updates and potential clinical applications. Mol Diagn Ther 2012; 16: 331-345.
2. Hesselink DA, Bouamar R, van Gelder T,. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Ther Drug Monit 2010; 32: 387-393.
3. Kamdem LK, Streit F, Zanger UM, et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 2005; 51: 1374-1381.
4. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23: 1315-1324.
5. Staatz CE, Goodman LK, Tett SE,. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet 2010; 49: 207-221.
6. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
7. Lee SJ, Usmani KA, Chanas B, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003; 13: 461-472.
8. Staatz CE, Goodman LK, Tett SE,. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet 2010; 49: 141-175.
9. Elens L, Bouamar R, Shuker N, Hesselink DA, van Gelder T, van Schaik RH,. Clinical implementation of pharmacogenetics in kidney transplantation: Calcineurin inhibitors in the starting blocks. Br J Clin Pharmacol 2014; 77: 715-728.
10. Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010; 87: 721-726.
11. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP,. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
12. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M,. Interindividual differences in hepatic expression of CYP3 A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 1999; 259: 201-205.
13. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W,. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011; 11: 274-286.
14. Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011; 57: 1574-1583.
15. Elens L, Capron A, van Schaik RH, et al. Impact of CYP3A4∗22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: Toward updated genotype-based dosage guidelines. Ther Drug Monit 2013; 35: 608-616.
16. Gijsen VM, van Schaik RH, Elens L, et al. CYP3A4∗22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. Pharmacogenomics 2013; 14: 1027-1036.